<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02721472</url>
  </required_header>
  <id_info>
    <org_study_id>DRE-FR-15-1</org_study_id>
    <nct_id>NCT02721472</nct_id>
  </id_info>
  <brief_title>Plasma DNA and Vascular Remodelling in Patients With Sickle Cell Disease</brief_title>
  <acronym>PADRE</acronym>
  <official_title>Plasma DNA and Vascular Remodelling in Patients With Sickle Cell Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ADDMEDICA SASA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ADDMEDICA SASA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the relationship between plasma DNA levels and
      micro- and macro-circulatory vascular remodelling in patients with sickle cell disease
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 17, 2016</start_date>
  <completion_date type="Actual">November 14, 2019</completion_date>
  <primary_completion_date type="Actual">November 14, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of plasma DNA levels in patients with a reactive hyperaemia index (RHI) &lt; 1.67 (endothelial dysfunction) assessed by Endo-PAT 2000 versus those recorded in patients with a RHI ≥ 1.67 (no endothelial dysfunction)</measure>
    <time_frame>1 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relationship between plasma DNA levels and cerebral micro- and macro-angiopathy assessed by CT angiography or MRI angiography and transcranial Doppler ultrasound</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between plasma DNA levels and cardiac damages</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between plasma DNA levels and pulmonary blood pressure</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between plasma DNA levels and macrocirculatory vascular measurements</measure>
    <time_frame>2 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between plasma DNA levels and nephropathy</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between plasma DNA levels and a clinical index of the sickle cell disease severity in a stable condition</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>sickle cell disease patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Sickle cell disease patients included in the study and Plasma DNA levels will be analyzed and compared in patients with a reactive hyperaemia index (RHI) &lt; 1.67 (endothelial dysfunction) assessed by Endo-PAT 2000 versus those recorded in patients with a RHI ≥ 1.67 (no endothelial dysfunction).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>micro- and macro-circulatory vascular remodelling measures not practice in routine care</intervention_name>
    <description>Vascular measures : reactive hyperaemia index (RHI) assessed by Endo-PAT, central aortic blood pressure, aortic augmentation index, carotid-femoral pulse wave velocity</description>
    <arm_group_label>sickle cell disease patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biological measures not practice in routine care</intervention_name>
    <description>Biological measures : Plasma DNA level, NETs (plasma nucleosome levels), Microparticules (MPs) (total, associated with red blood cells, neutrophils, platelets), haem (total and bound to MPs), Myeloperoxydase and elastase activity, neutrophils/DNA, Annexin A5, RNA and TSP1</description>
    <arm_group_label>sickle cell disease patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years.

          -  Homozygous SS or Sß0 sickle cell disease patients.

          -  Seen in consultation for an annual clinical and para-clinical evaluation of his/her
             disease.

          -  Stable clinical condition of the disease defined as the absence of severe
             vaso-occlusive crises (requiring hospitalisation or a visit to the emergency unit) in
             the previous month and absence of transfusion in the previous 3 months.

        Exclusion Criteria:

          -  Other haemoglobinopathy

          -  Known diabetes.

          -  Recent administration of an anticoagulant treatment at curative doses (&lt; 48h before
             inclusion), or platelet-inhibiting drugs (less than 1 week prior to inclusion).

          -  Recent transfusion (less than 3 months prior to inclusion).

          -  Pregnancy or post-partum (first 40 days after giving birth).

          -  Recent consumption of alcohol (less than 10h), coffee (less than 3h), and tobacco
             (less than 36h) before inclusion.

          -  Known infection with hepatitis B, C, and HIV infection.

          -  Known cancer or progressive blood disease.

          -  Known haemostasis or coagulation disorders.

          -  Progressive inflammatory or infectious diseases.

          -  Recent history (dating less than 3 months) of venous (pulmonary embolism, deep venous
             thrombosis) or arterial (acute coronary syndrome, stroke, peripheral arterial
             ischaemia) thromboembolic event.

          -  Adult patients subject to legal protection measures.

          -  Patients already involved in a therapeutic protocol.

          -  Patients not affiliated to a social security system.

          -  Non-inclusion criteria related to the technical requirements of the Endo-PAT:

               -  Known cardiac arrhythmia.

               -  Severe Raynaud's syndrome.

               -  Hand or arm deformity that prevents an EndoPAT analysis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>LE JEUNE Sylvain, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Avicenne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <state>Ile De France</state>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>March 18, 2016</study_first_submitted>
  <study_first_submitted_qc>March 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2016</study_first_posted>
  <last_update_submitted>January 7, 2020</last_update_submitted>
  <last_update_submitted_qc>January 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>Vascular Remodeling</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

